Rocket Pharmaceuticals(RCKT) - 2025 Q4 - Annual Results
Rocket Pharmaceuticals(US:RCKT)2026-02-26 21:21"In 2025, we strengthened Rocket's leadership in cardiovascular gene therapy, supported by more than five years of clinical experience in Danon disease and continued advancement across our PKP2-ACM and BAG3-DCM programs," said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals. "Our focus remains on rigorous clinical execution across three cardiovascular programs, including resuming the Phase 2 pivotal clinical trial in Danon disease, initiating the Phase 1 clinical trial in BAG3-DCM, and ...